Agilent and CRO PureHoney will develop new applications for the RapidFire 365 system, including workflows for pharmaceutical research, forensics, and metabolomics.
Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
Under the terms of the agreement, M3 and G-TAC will promote 14 Pathway tests through G-TAC's personalized medicine platform connected to M3's physician network.
Under the agreement, Genomic Health will make an undisclosed equity investment in Epic Sciences, and will have exclusive rights to market its test in the US.
The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.
The deal gives SouthGenetics marketing rights for MDxHealth's ConfirmMDx test for prostate cancer in 12 countries, including Mexico, Argentina, and Colombia.
The deal will provide researchers a fully automated solution for immunostaining captured circulating tumor cells deposited on microscope slides.
The deal provides customers a complete end-to-end solution for cytogenomic array and next-generation sequencing services, the firms said.
The partners will co-market the Phenomenex Strata and Strata-X SPE sorbents adapted to Tecan's Freedom EVO series of robotic workstations.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.